Open Access Open Access  Restricted Access Subscription Access
Open Access Open Access Open Access  Restricted Access Restricted Access Subscription Access

Formulation and Evaluation of Prolong Release Tablet of Anti-Hypertensive Drug


Affiliations
1 HSBPVT's College of Pharmacy, Kashti, India
     

   Subscribe/Renew Journal


Formulation of Prolonged release dosage form has a slower absorption rate than immediate release formulation and shows minimal fluctuation in plasma levels during steady state dosing interval. Additionally, the Once-daily dosage regimen has better patient compliance. Prolonged release tablet of Anti-hypertensive drug with Eudragit RS 30 D using wet granulation method yielded optimum results and process parameters like granulation spray rate and compression machine rotor speed was found robust product development. Stability studies showed that the formulation was stable after being kept at condition of 40° ± 2° C/75% RH, for period of 3 months. The formulated product gave a dissolution profile similar to that of the innovator product (f2 value>80).

Keywords

Prolonged Release Dosage Form, Plasma Levels, Eudragit Rs, Stability Studies, F2 Value.
Subscription Login to verify subscription
User
Notifications
Font Size


  • Ali Nokhodchi, Saishta Raja, The role of oral controlled release matrix tablets in drug delivery system; Bioimpacts; 2012; v2(4); 175-187.
  • Nellore RV, Development of extended release matrix tablet formulation for regulatory policy consideration, controlled release, 1998, Jan 2, 50(1-3),24756.
  • Honey priyajames, smart polymers for controlled delivery of drugs, Acta Pharmaceutics Sinica B, April 2014, V-4, I-2, pg (120-27).
  • ICH guidelines, Q1A (R2): Stability Testing of New Drug Substances and Products (Revision 2), International Conference on Harmonization.
  • ICH Harmonised Tripartite Guideline stability testing: Photo stability testing of new drug substances and products Q1B.
  • Harnish Patel et al, Matrix Type Drug Delivery System: A Review, Journal of Pharmaceutical Sciences and Bioscientific Research, 2011, 1(3), 143-151.
  • Shalaka Dhat et al, Effect of Two Different Diluents On Release Profile Of Aceclofenac From Sustained Release Matrix Tablets Using Gum Damar As Release Retardant, International Journal of Pharmacy and Pharmaceutical Sciences, 2011, 3(4), 307-313.
  • Borguist P, Korner A, Larsson A: A model for the drug release from a polymeric matrix tablets-effect of swelling and dissolution. Journal of Controlled Release, 2006, 113, 216-225.
  • John C and Morten C. The Science of Dosage Form Design, Aulton: Modified release peroral dosage forms, 2nd edition, London, Churchill Livingstone; 2002, p. 290-300.
  • Basak SC, Reddy JBM, and Lucas Mani KP, Formulation and release behaviour of sustained release ambroxol hydrochloride HPMC matrix tablet, Indian Journal of Pharmaceutical Sciences, 2006, 5(68), 594-598.

Abstract Views: 1

PDF Views: 0




  • Formulation and Evaluation of Prolong Release Tablet of Anti-Hypertensive Drug

Abstract Views: 1  |  PDF Views: 0

Authors

Pradip Choudhari
HSBPVT's College of Pharmacy, Kashti, India

Abstract


Formulation of Prolonged release dosage form has a slower absorption rate than immediate release formulation and shows minimal fluctuation in plasma levels during steady state dosing interval. Additionally, the Once-daily dosage regimen has better patient compliance. Prolonged release tablet of Anti-hypertensive drug with Eudragit RS 30 D using wet granulation method yielded optimum results and process parameters like granulation spray rate and compression machine rotor speed was found robust product development. Stability studies showed that the formulation was stable after being kept at condition of 40° ± 2° C/75% RH, for period of 3 months. The formulated product gave a dissolution profile similar to that of the innovator product (f2 value>80).

Keywords


Prolonged Release Dosage Form, Plasma Levels, Eudragit Rs, Stability Studies, F2 Value.

References